Laurion Capital Management LP Altimmune, Inc. Transaction History

Laurion Capital Management LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$3.45 - $5.97 $5.73 Million - $9.92 Million	-1,661,726 Reduced 47.46%	1,839,604 $6.49 Million
Q1 2023 May 15, 2023	BUY	$4.19 - $16.83 $11.5 Million - $46.3 Million	2,750,030 Added 366.04%	3,501,330 $14.8 Million
Q4 2022 Feb 14, 2023	BUY	$8.74 - $16.45 $10,444 - $19,657	1,195 Added 0.16%	751,300 $12.4 Million
Q3 2022 Nov 14, 2022	SELL	$10.67 - $22.41 $147,939 - $310,714	-13,865 Reduced 1.81%	750,105 $9.58 Million
Q2 2022 Aug 15, 2022	BUY	$3.94 - $11.77 $3.01 Million - $8.99 Million	763,970 New	763,970 $8.94 Million

186

39.3M

913K

743K

Ticker ALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 49,025,300
Market Cap $370M
Description
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.